Cyclopentyl-pyrimidine based analogues as novel and potent IGF-1R inhibitor

Eur J Med Chem. 2015 Mar 6:92:246-56. doi: 10.1016/j.ejmech.2014.12.053. Epub 2014 Dec 31.

Abstract

A series of novel 2-amino-4-pyrazolecyclopentylpyrimidines have been prepared and evaluated as IGF-1R tyrosin kinase inhibitors. The in vitro activity was found to depend strongly on the substitution pattern in the 2- amino ring, 4-pyrazolo moieties and size of fused saturated ring with the central pyrimidine core. A stepwise optimization by combination of active fragments led to discovery of compound 6f and 6k, two structures with IGF-1R IC50 of 20 nM and 10 nM, respectively. 6f was further profiled for its anti cancer activity across various cell lines and pharmacokinetic studies in Sprague Dawley rats.

Keywords: Anti-cancer; Insulin-like growth factor-1 receptor (IGF-IR); Kinase inhibitors; Pyrazoles; Pyrimidines.

MeSH terms

  • Animals
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Cyclopentanes / chemical synthesis
  • Cyclopentanes / chemistry*
  • Cyclopentanes / pharmacology*
  • Dose-Response Relationship, Drug
  • Humans
  • Models, Molecular
  • Molecular Structure
  • Protein Kinase Inhibitors / chemical synthesis
  • Protein Kinase Inhibitors / chemistry*
  • Protein Kinase Inhibitors / pharmacology*
  • Pyrimidines / chemical synthesis
  • Pyrimidines / chemistry*
  • Pyrimidines / pharmacology*
  • Rats
  • Rats, Sprague-Dawley
  • Receptor, IGF Type 1 / antagonists & inhibitors*
  • Receptor, IGF Type 1 / metabolism
  • Structure-Activity Relationship

Substances

  • Cyclopentanes
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Receptor, IGF Type 1
  • pyrimidine